Back to top
more

Oramed Pharmaceuticals Inc. (ORMP)

(Delayed Data from NSDQ)

$22.48 USD

22.48
347,565

+0.42 (1.90%)

Updated Oct 18, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (167 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Fiscal Year End for Oramed Pharmaceuticals Inc. falls in the month of August.

All items in Millions except Per Share data.

8/31/2021 8/31/2020 8/31/2019 8/31/2018 8/31/2017
Assets          
Cash & Equivalents NA 40 32 30 20
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 1 1 1 0
Total Current Assets NA 41 33 31 20
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 4 1 16 18
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 45 35 47 39
Liabilities & Shareholders Equity 8/31/2021 8/31/2020 8/31/2019 8/31/2018 8/31/2017
Notes Payable NA 0 0 0 0
Accounts Payable NA 2 3 2 3
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 3 3 2 2
Total Current Liabilities NA 5 5 5 5
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 7 10 11 14
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 12 15 16 19
Shareholders Equity 8/31/2021 8/31/2020 8/31/2019 8/31/2018 8/31/2017
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 125 100 99 75
Retained Earnings NA -93 -81 -69 -57
Other Equity NA 0 0 1 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 33 19 31 19
Total Liabilities & Shareholder's Equity NA 45 35 47 39
Total Common Equity 0 33 19 31 19
Shares Outstanding 32.50 23.50 17.30 17.30 13.30
Book Value Per Share 0.00 1.40 1.12 1.80 1.45

Fiscal Year End for Oramed Pharmaceuticals Inc. falls in the month of August.

All items in Millions except Per Share data.

8/31/2021 5/31/2021 2/28/2021 11/30/2020 8/31/2020
Assets          
Cash & Equivalents NA 70 57 34 40
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 3 1 2 1
Total Current Assets NA 72 57 36 41
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 7 3 4 4
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 80 62 41 45
Liabilities & Shareholders Equity 8/31/2021 5/31/2021 2/28/2021 11/30/2020 8/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 3 3 3 2
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 3 3 3 3
Total Current Liabilities NA 6 6 6 5
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 5 6 6 7
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 11 12 13 12
Shareholders Equity 8/31/2021 5/31/2021 2/28/2021 11/30/2020 8/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 176 152 126 125
Retained Earnings NA -108 -103 -98 -93
Other Equity NA 1 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 69 49 28 33
Total Liabilities & Shareholder's Equity NA 80 62 41 45
Total Common Equity 0 69 49 28 33
Shares Outstanding 32.50 30.20 29.30 23.60 23.50
Book Value Per Share 0.00 2.29 1.69 1.20 1.40